Aroa Soriano

1.6k total citations
31 papers, 956 citations indexed

About

Aroa Soriano is a scholar working on Molecular Biology, Neurology and Cancer Research. According to data from OpenAlex, Aroa Soriano has authored 31 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 12 papers in Neurology and 7 papers in Cancer Research. Recurrent topics in Aroa Soriano's work include Neuroblastoma Research and Treatments (12 papers), Protein Degradation and Inhibitors (8 papers) and Receptor Mechanisms and Signaling (6 papers). Aroa Soriano is often cited by papers focused on Neuroblastoma Research and Treatments (12 papers), Protein Degradation and Inhibitors (8 papers) and Receptor Mechanisms and Signaling (6 papers). Aroa Soriano collaborates with scholars based in Spain, Italy and Ireland. Aroa Soriano's co-authors include Rafael Franco, Miguel F. Segura, Soledad Gallego, Josep Roma, Carme Lluı́s, Vicent Casadó, Joan Sánchez-de-Toledo, Luz Jubierre, Francisco Ciruela and Jorge Gandía and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Oncogene.

In The Last Decade

Aroa Soriano

31 papers receiving 944 citations

Peers

Countries citing papers authored by Aroa Soriano

Since Specialization

Citations

This map shows the geographic impact of Aroa Soriano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aroa Soriano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aroa Soriano more than expected).

Fields of papers citing papers by Aroa Soriano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aroa Soriano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aroa Soriano. The network helps show where Aroa Soriano may publish in the future.

Co-authorship network of co-authors of Aroa Soriano

This figure shows the co-authorship network connecting the top 25 collaborators of Aroa Soriano. A scholar is included among the top collaborators of Aroa Soriano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aroa Soriano. Aroa Soriano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma 2024 ·PLoS ONE ·Catherine Murphy, Laura Devis, (unknown), (unknown), Ciara M Gallagher, (unknown), (unknown), Aroa Soriano, Stephen F. Madden, Josep Roma, Miguel F. Segura, Olga Piskareva	2
2	Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program 2022 ·Molecular Cancer ·Carlos Jiménez, (unknown), Mariona Nadal‐Ribelles, Laura Devis, (unknown), Carme Solé, (unknown), (unknown), Aroa Soriano, Joan Sánchez-de-Toledo, David Llobet‐Navàs, Josep Roma, Francesc Posas, Eulàlia de Nadal, Soledad Gallego, Lucas Moreno, Miguel F. Segura	7
3	Multi-Smart and Scalable Bioligands-Free Nanomedical Platform for Intratumorally Targeted Tambjamine Delivery, a Difficult to Administrate Highly Cytotoxic Drug 2021 ·Biomedicines ·Marta Pérez-Hernández, (unknown), (unknown), (unknown), (unknown), Aroa Soriano, David Martínez‐García, Alain Arias, María García‐Valverde, Miguel F. Segura, Roberto Quesada, (unknown), Vanessa Soto‐Cerrato, Ricardo Pérez‐Tomás	8
4	Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance 2020 ·Cell Death and Disease ·(unknown), (unknown), (unknown), Jaume Mora, Aroa Soriano, Gabriela Guillén, Soledad Gallego, Josep Roma, Josep Samitier, Alberto Villanueva, Joan Montero	19
5	miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma 2020 ·Cancer Letters ·(unknown), (unknown), (unknown), (unknown), Gabriel Gallo-Oller, Guillem Pons, (unknown), Lucas Moreno, Gabriela Guillén, Raquel Hladun, M Garrido, Aroa Soriano, Miguel F. Segura, Joan Sánchez-de-Toledo, Soledad Gallego, Josep Roma	22
6	The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis 2020 ·Cell Death and Disease ·(unknown), Aroa Soriano, Carlos Jiménez, Tatiana Erazo, (unknown), (unknown), (unknown), (unknown), José Alfón, Héctor Perez‐Montoyo, Marc Yeste‐Velasco, (unknown), Josep Roma, Joan Sánchez-de-Toledo, Lucas Moreno, José M. Lizcano, Soledad Gallego, Miguel F. Segura	6
7	Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma 2019 ·Cellular and Molecular Life Sciences ·Aroa Soriano, (unknown), (unknown), (unknown), (unknown), Olga Piskareva, Carlos Jiménez, Kai‐Oliver Henrich, Josep Roma, Frank Westermann, Raymond L. Stallings, Constantino Sábado, Joan Sánchez-de-Toledo, Anna Santamaría, Soledad Gallego, Miguel F. Segura	30
8	Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer 2019 ·Frontiers in Oncology ·(unknown), (unknown), Carlos Jiménez, (unknown), Aroa Soriano, Josep Roma, Joan Sánchez-de-Toledo, Soledad Gallego, Miguel F. Segura	13
9	miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer 2017 ·Cell Death and Disease ·Andrea Feliciano, Yoelsis Garcia‐Mayea, Luz Jubierre, Cristina Mir, Manuela Hummel, Josep Castellví, Javier Hernández‐Losa, Rosanna Paciucci, Irene Sansano, Yilin Sun, Santiago Ramón y Cajal, (unknown), Aroa Soriano, Miguel F. Segura, Alex Lyakhovich, Matilde E. Lleonart	75
10	Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands 2017 ·British Journal of Cancer ·Ana Almazán-Moga, (unknown), (unknown), Pablo Velasco, (unknown), Katja Simon‐Keller, (unknown), (unknown), (unknown), Miguel F. Segura, Aroa Soriano, S. Navarro, Òscar M. Tirado, Joan Carles Ferreres, Anna Santamaría, Rossella Rota, Heidi Hahn, Joan Sánchez-de-Toledo, Josep Roma, Soledad Gallego	23
11	BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways 2016 ·Oncogene ·Luz Jubierre, Aroa Soriano, (unknown), (unknown), Stephan P. Tenbaum, Octavio A. Romero, Rana S. Moubarak, Ana Almazán-Moga, (unknown), Josep Roma, S. Navarro, (unknown), Montse Sánchez‐Céspedes, Joan X. Comella, Héctor G. Pálmer, Joan Sánchez-de-Toledo, Soledad Gallego, Miguel F. Segura	52
12	Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments 2016 ·Clinical & Translational Oncology ·(unknown), (unknown), (unknown), (unknown), Ana Almazán-Moga, (unknown), Aroa Soriano, Miguel F. Segura, Raquel Hladun, Alberto Villanueva, Soledad Gallego, Josep Roma	13
13	Nuevas estrategias terapéuticas para el neuroblastoma basadas en el uso de microRNAs 2015 ·Anales de Pediatría ·(unknown), (unknown), Aroa Soriano, Josep Roma, Soledad Gallego, Joan Sánchez-de-Toledo, Miguel F. Segura	5
14	MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness 2014 ·Cell Death and Disease ·(unknown), (unknown), Aroa Soriano, Stéphanie Reix, Derek Murphy, Joan Carles Ferreres, Francesc E. Borràs, Soledad Gallego, R. L. Stallings, Rana S. Moubarak, Miguel F. Segura, Joan X. Comella	15
15	microRNAs as pharmacological targets in cancer 2013 ·Pharmacological Research ·Aroa Soriano, Luz Jubierre, Ana Almazán-Moga, (unknown), Josep Roma, Joan Sánchez-de-Toledo, Soledad Gallego, Miguel F. Segura	47
16	Adenosine receptors interacting proteins (ARIPs): Behind the biology of adenosine signaling 2009 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Francisco Ciruela, (unknown), Aroa Soriano, (unknown), Lourdes Carbonell, Sílvia Sánchez, Jorge Gandía, Víctor Fernández‐Dueñas	60
17	Indoloquinolizidine–Peptide Hybrids as Multiple Agonists for D₁ and D₂ Dopamine Receptors 2009 ·ChemMedChem ·Marc Vendrell, Aroa Soriano, Vicent Casadó, (unknown), Rodolfo Lavilla, Enric I. Canela, Carme Lluı́s, Rafael Franco, Fernando Alberício, Míriam Royo	15
18	A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Aroa Soriano, Marc Vendrell, Sergio González‐Torres, Josefa Mallol, Fernando Alberício, Míriam Royo, Carmen Lluís, Enric I. Canela, Rafael Franco, Antoni Cortés, Vicent Casadó	12
19	Identification of Dopamine D1–D3 Receptor Heteromers 2008 ·Journal of Biological Chemistry ·Daniel Marcellino, Sergi Ferré, Vicent Casadó, Antonio Cortés, Bernard Le Foll, Carmen Mazzola, Filippo Drago, (unknown), Holger Stark, Aroa Soriano, Chanel Barnes, Steven R. Goldberg, Carme Lluı́s, Kjell Fuxé, Rafael Franco	193
20	Detection of higher‐order G protein‐coupled receptor oligomers by a combined BRET–BiFC technique 2008 ·FEBS Letters ·Jorge Gandía, Jorge Galino, Olavo B. Amaral, Aroa Soriano, Carme Lluı́s, Rafael Franco, Francisco Ciruela	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact